{
  "id": 16597315,
  "title": "H.C. Wainwright lowers Balchem stock price target on revenue miss",
  "url": "https://urgent.news/2026/10/26/h-c-wainwright-lowers-balchem-stock-price-target-on-revenue-miss",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-26T11:52:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-lowers-balchem-stock-price-target-on-revenue-miss-93CH-4972364"
  },
  "original_language": "en",
  "account": "H.C. Wainwright has revised its price target for Balchem (BCPC) to $210 from $215, while keeping its Buy rating intact. The downgrade stems from a slight miss in revenue during the company's third quarter. Balchem reported revenue of $290.7 million, which was below the firm's estimate of $292.2 million, despite an 8.6% increase compared to the same period last year. The company's market capitalization stands at $4.27 billion, with revenue growth of 10.5% over the past year. H.C. Wainwright projects full-year 2026 revenue to be around $1.143 billion, only marginally different from its previous estimate of $1.145 billion.\n\nIn terms of earnings, Balchem's third-quarter GAAP net earnings were $1.46 per diluted share, surpassing the firm's forecast of $1.41 per share. The company has raised its full-year 2026 earnings forecast to $5.54 per diluted share from $5.43 per share. The decline in the applied price-to-earnings multiple, now at 38.5 times from 39.6 times, prompted the price target adjustment.\n\nBalchem's Human Nutrition and Health division met revenue expectations with $188.3 million, exceeding H.C. Wainwright's forecast of $179 million. However, the animal health and nutrition segment fell short, reporting sales of approximately $63 million, which was lower than the projected $70 million. H.C. Wainwright's analysis suggests that the stock is trading at a high earnings multiple, and it offers comprehensive Pro Research Reports for investors seeking clear, actionable intelligence. The firm has maintained its full-year 2027 revenue forecast at $1.22 billion, raising its earnings forecast to $5.50 per share from $5.43 per share.\n\nBalchem Corp. recently reported its third-quarter 2026 financial results, surpassing analysts' expectations with adjusted earnings of $1.57 per share, outpacing the estimated $1.43. Revenue for the quarter reached $290.7 million, slightly above forecasts and representing an 8.6% increase from the previous year. The company credited the growth in sales to higher volumes, improved product mix, and manufacturing efficiencies that helped offset inflationary pressures. Balchem's gross margin also widened during this period. Despite these positive developments, no analyst firms have upgraded or downgraded Balchem Corp. in response to these results.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}